Agenus Says Published Phase 1b Data Showed 21.2-Month Median Overall Survival, 33% Three-Year Overall Survival And 21% Objective Response Rate With Botensilimab Plus Balstilimab In 123 Pretreated MSS Colorectal Cancer Patients

Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and

Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients

Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of

Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026

Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday

U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.